Washington, D.C. Location
Washington, DC 20015
Princeton, NJ Location
Princeton, NJ 08540
McNeely, Hare & War LLP
5335 Wisconsin Ave, NW
Washington, DC 20015
Phone: +01 202 640-1801
William Hare practices patent law in the technology areas of biotechnology, chemistry and pharmaceuticals. Mr. Hare has managed an IP-portfolio for a major international pharmaceutical corporation where he held the title of Senior Counsel of Intellectual Property. Having worked as in-house counsel, Mr. Hare is attuned to the needs of large corporations and the importance of communication and cooperation between in-house and private counsel.
During his tenure as Senior Counsel, Mr. Hare prepared and prosecuted numerous patent applications worldwide as part of a global intellectual property portfolio designed to further his corporation’s global business goals. His other duties as Senior Counsel included preparing freedom-to-operate opinions and conducting due diligence for the corporation’s acquisitions. In this role, he also provided litigation support in furtherance of his corporation’s business interests. Mr. Hare also has taken an active position in global intellectual property issues as a panelist participating in World Intellectual Property Organization seminars.
Prior to becoming in-house counsel, Mr. Hare practiced patent law in Washington, DC at two national law firms, Fish & Richardson, P.C. and Hogan & Hartson LLP. As part of his practice, Mr. Hare prosecuted patent applications for several major foreign and multinational corporations.
Mr. Hare also brings real world engineering experience to his practice of law. Prior to beginning his career in law, Mr. Hare was an engineer with Mallinckrodt Medical. During this time he worked on radiology and magnetic resonance imaging systems, ultrasound devices, wireless remote controls and monitoring devices for infusion systems, ultrasonic nebulizers, and pulse oximetry monitors and sensors.
Mr. Hare has an undergraduate degree in Chemical Engineering and a Masters of Science degree in Biomedical Engineering, both from Clemson University. He has also obtained law and MBA degrees from the University of Houston. While working in the patent field, he has continued to further his education by obtaining a Masters of Science degree in Biotechnology from the Johns Hopkins University.
Pfizer Inc. and UCB Pharma GMBH v. Amerigen Pharmaceuticals, Inc. and Amerigen Pharmaceuticals Ltd., 13-cv-1156 (D. Del). Representing Amerigen in the defense of a patent infringement case for the filing of a NCE-1, FTF ANDA case for the pharmaceutical product, Toviaz® (fesoterodine).
Astrazeneca AB, Aktiebolaget Hassle, Astrazeneca LP, KBI, Inc. and KBI-E Inc. v. Wockhardt Limited and Wockhardt USA LLC, 13-cv-04854 (D. NJ). Representing Wockhardt in the defense of a patent infringement case of the filing of an ANDA case for the pharmaceutical product, Nexium® (esomeprazole).
Chico’s FAS, Inc. v. 1654754 Ontario, Inc. d/b/a Wink Intimates, 13-cv-00792 (M.D. FL). Representing Wink Intimates and its owners in the defense of a Declaratory Judgment action asserting noninfringement and invalidity of utility and design patents covering a tank top-camisole product.
Neuroptics, Inc. v. NYCTM a.k.a. New York City Technology in Medicine, 13cv00770 (C.D. CA). Represented NYCTM and its owners in the defense of a patent case alleging patent infringement by NYCTM’s mobile medical app for diagnosing concussions and substance abuse. Obtained settlement and dismissal of case.
Forest Laboratories, Inc. and Forest Laboratories Holdings, Ltd. v. Amerigen Pharmaceuticals Inc. and Amerigen Pharmaceuticals Ltd., 12-cv-5026 (E.D. Ill). Represented Amerigen in the defense of a patent infringement case for the filing of a NCE-1, FTF ANDA case for the pharmaceutical product, Bystolic® (nebivolol). Obtained settlement and dismissal of case.
Deston Therapeutics, LLC and Unigen Pharmaceuticals, Inc. v. Trigen Laboratories, Inc. and Irisys, Inc., 09-cv-00809 (D. Del). Represented Trigen and Irisys in defense of a patent infringement and Lanham Act violation litigation for a generic alternative to Auralgan® eye drops. Obtained settlement and dismissal of case.